Telehealth company Hims & Hers dropped its plan to offer a knockoff version of the weight-loss pill Wegovy on Saturday — two days after it announced the new drug ...

Hims & Hers shares jumped more than 50% in premarket trade on Monday after ending a dispute with Novo Nordisk by striking a ...

With more people taking the weight-loss drugs Wegovy and Zepbound, one question inevitably arises: which one is more ...

Ozempic maker's lawsuit, FDA enforcement could curtail sales of less expensive, compounded, versions of popular weight loss ...

The global obesity epidemic has spurred pharmaceutical companies to invest heavily in developing effective weight management solutions, leading to a surge in clinical trials for anti-obesity ...

Eli Lilly announced on "Good Morning America" Monday that its GLP-1 weight-loss drug Zepbound will now be available in a new ...

Lilly's Zepbound surpasses Wegovy in dollar sales, while pricing cuts and copycats pressure Novo's growth outlook.

Drugmaker Novo Nordisk plans to slash list prices for its wildly popular weight-loss and diabetes drugs Wegovy and Ozempic by ...

Losing weight with the help of a prescription weight loss drug continues to increase in popularity. According to recent KFF polls, about one in eight U.S. adults takes a GLP-1 medication for ...

The price of the company's popular GLP-1 drugs could come down by as much as 50% next year.

A few months into GLP-1 treatment, many patients encounter an unexpected and distressing side effect: significant hair loss.